This blog is written by our clinicians and aims to keep patients informed with up to date information on medical conditions.
For decades contraception has fallen to the female in most couples, due to the effectiveness of female contraceptives and the lack of a satisfactory male alternative.
Current reversible methods consist of ‘pulling out’, which is not effective, or using condoms. Condoms, while very effective if used correctly, are not popular with most men as they affect sexual enjoyment. They, of course, still have a major role in prevention of sexually transmitted infection.
However, good news is on the horizon as three new methods of male contraception are currently being researched and are progressing well.
The gel contains Testosterone and Segestone which is a synthetic form of the female progesterone hormone.
A metered dose of gel is applied to the shoulders and arms daily and the progestin shuts down the hormones that stimulate testosterone production in the testes. Lowering testosterone production decreases sperm production.
The gel takes 6-12 weeks to achieve a lowered sperm count and takes the same time to reverse fertility if it is stopped.
You might wonder if lowering the testosterone level will have side effects such as decreased libido and erectile dysfunction, but that is why there is testosterone in the gel to keep hormonal balance.
A trial of 450 couples has just started with UK participants. As the current trial will take over a year, the gel is still years off coming to the market, but it looks very promising. Recruitment is ongoing for men aged between 18 and 50 who are in a stable relationship with a woman between 18 and 34. The number to phone if you wish to take part in the trial is 0131 242 2669 ( Edinburgh) or 0161 276 3296( Manchester).
It has proved difficult to develop a male contraceptive pill that decreases sperm but does not give unwanted side effects. However DMAU – Dimethandrolone undecanoate is showing promise. It works in a similar way to the gel as it has the properties of both progestin and testosterone. This drug has been well tolerated but more evidence is needed regarding its ability to suppress sperm production. This is definitely a work in progress.
This involves injection under guidance of a non-toxic synthetic chemical which is injected into the vas deferens (collecting tube from testis). It blocks the vas deferens and reacts with the sperm killing any that come into contact with it. It is effective almost immediately and it can be washed out if the man decides to have family later.
This is a similar to RISUG but instead a plug is placed in the vas deferens. This blocks the vas and filters out sperm. It can be removed if family is planned. Further research is needed into the effectiveness and safety of this method but it looks promising.
The other option for men who have completed their family is vasectomy. This involves cutting, blocking or sealing the vas deferens, thereby preventing sperm getting into the semen. It is considered 99% effective.
The procedure if performed under local anaesthetic usually, but sometimes under general anaesthetic. It is considered permanent, as it is difficult to reverse. Hormones are not affected so the sex drive remains and erections and ejaculation should not be affected.
Contraception is needed until testing confirms that there is no sperm in the semen. Two or more semen samples will need to be submitted to the laboratory to confirm all the sperm has gone, so it can take 4-6 months until fertility is curtailed.
If you would like to talk about any of these matters to a doctor, do get in touch.
EUROPEAN PHARMACEUTICAL REVIEW, April 2019, Second potential male birth control pill passes human safety tests, accessed 27th June 2019,<http://European pharmaceutical review.com/news/8607/second-
NHSINFORM, February 2019, The pill for men, accessed 27th June 2019,<http://nhsinform.scot/
SKY NEWS,25th June 2019, Male contraceptive gel:UK man among first in world to take part in trials, accessed 27th June 2019,< https://news.sky.com/story/
In England we are registered with the Care Quality Commission. For our full report please click the link below.
In Scotland we are regulated by Healthcare Improvement Scotland. For our report please click the link below.
Copyright © 2024 ROC Clinics UK LTD | Privacy Policy | Contact | Terms & Conditions for Quotations, Prices, Sales and Pre-payments
Registered office address: (C/O Thrings Llp) 6, Drakes Meadow, Swindon, England, SN3 3LL
CQC Provider ID: 1-16939474257 | CQC Location ID 1-17052847559 | HIS Registration No 00413
Duty of Candour Annual Report 2024
ROC is a trading name on behalf of ROC Health Group Ltd and ROC Clinics UK LTD
Cookie | Duration | Description |
---|---|---|
AnalyticsSyncHistory | 1 month | No description |
li_gc | 2 years | No description |
Cookie | Duration | Description |
---|---|---|
_fbp | 3 months | This cookie is set by Facebook to display advertisements when either on Facebook or on a digital platform powered by Facebook advertising, after visiting the website. |
fr | 3 months | Facebook sets this cookie to show relevant advertisements to users by tracking user behaviour across the web, on sites that have Facebook pixel or Facebook social plugin. |
IDE | 1 year 24 days | Google DoubleClick IDE cookies are used to store information about how the user uses the website to present them with relevant ads and according to the user profile. |
test_cookie | 15 minutes | The test_cookie is set by doubleclick.net and is used to determine if the user's browser supports cookies. |
Cookie | Duration | Description |
---|---|---|
__hstc | 1 year 24 days | This is the main cookie set by Hubspot, for tracking visitors. It contains the domain, initial timestamp (first visit), last timestamp (last visit), current timestamp (this visit), and session number (increments for each subsequent session). |
_ga | 2 years | The _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors. |
_gat_UA-19477224-1 | 1 minute | A variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to. |
_gcl_au | 3 months | Provided by Google Tag Manager to experiment advertisement efficiency of websites using their services. |
_gid | 1 day | Installed by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously. |
hubspotutk | 1 year 24 days | HubSpot sets this cookie to keep track of the visitors to the website. This cookie is passed to HubSpot on form submission and used when deduplicating contacts. |
Cookie | Duration | Description |
---|---|---|
__cf_bm | 30 minutes | This cookie, set by Cloudflare, is used to support Cloudflare Bot Management. |
__hssc | 30 minutes | HubSpot sets this cookie to keep track of sessions and to determine if HubSpot should increment the session number and timestamps in the __hstc cookie. |
bcookie | 2 years | LinkedIn sets this cookie from LinkedIn share buttons and ad tags to recognize browser ID. |
bscookie | 2 years | LinkedIn sets this cookie to store performed actions on the website. |
lang | session | LinkedIn sets this cookie to remember a user's language setting. |
lidc | 1 day | LinkedIn sets the lidc cookie to facilitate data center selection. |
UserMatchHistory | 1 month | LinkedIn sets this cookie for LinkedIn Ads ID syncing. |